Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMARZHU)

• Drug Name: N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine Drug Info
• Synonyms: DNVZYSMOLXCOLY-HNNXBMFYSA-N; UAMC00039; CHEMBL98869; SCHEMBL6824340; GTPL6538; ZINC13561228; BDBM50146972; NCGC00379239-01; 1-[(S)-2-Amino-4-[(4-chlorobenzyl)amino]butyryl]piperidine; (S)-4-(4-chlorobenzylamino)-2-amino-1-(piperidin-1-yl)butan-1-one; (2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one; 2-(S)-Amino-4-(4-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11232124
  TTD Drug ID: DMARZHU

Molecule-Related Drug Atlas

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[4]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[5]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[6]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[7]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[8]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[9]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[10]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[11]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[12]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[13]

Drug(s) Targeting Dipeptidyl-peptidase 7 (DPP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BDBM50382283	DMQJ5S8	N. A.	N. A.	Patented	[14]
BDBM50434165	DMDTYJ9	N. A.	N. A.	Patented	[14]
BDBM50434164	DM6DFTX	N. A.	N. A.	Patented	[14]
US8470836, 5	DMYR10P	N. A.	N. A.	Patented	[15]
US8470836, 8	DMM4GLH	N. A.	N. A.	Patented	[15]
CRWCYVOHVXAEMF-LBPRGKRZSA-N	DMBV5Z0	N. A.	N. A.	Patented	[14]
US8470836, 2	DMH7JVA	N. A.	N. A.	Patented	[15]
US8470836, 6	DMVYQXH	N. A.	N. A.	Patented	[15]

Drug(s) Affected By Dipeptidyl peptidase 2 (DPP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[17]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[19]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[20]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[21]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Inhibitor	[2]
Dipeptidyl-peptidase 7 (DPP7)	TTOYT5L	DPP2_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Dipeptidyl peptidase 2 (DPP7)	OT0P5C6T	DPP2_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6538).
• [2] Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4777-9.
• [3] Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 2006 Jun 28;72(1):70-9.
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [6] Clinical pipeline report, company report or official report of Takeda (2009).
• [7] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [8] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [11] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [12] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [13] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [14] FAP inhibitors. US9346814.
• [15] Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.
• [16] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [17] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [18] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [19] Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology. 2008 Oct;149(10):4809-20. doi: 10.1210/en.2008-0035. Epub 2008 Jun 12.
• [20] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [21] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [22] Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells. Toxicol Appl Pharmacol. 2020 Sep 15;403:115160. doi: 10.1016/j.taap.2020.115160. Epub 2020 Jul 25.
• [23] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [24] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.